We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Lunit AI-Powered Pathology Solution Aids Highly Accurate Cancer Diagnosis

By LabMedica International staff writers
Posted on 28 Apr 2022
Print article
Image: Lunit SCOPE PD-L1 (Photo courtesy of Lunit)
Image: Lunit SCOPE PD-L1 (Photo courtesy of Lunit)

Programmed death ligand 1 (PD-L1) expression is the standard biomarker in advanced non-small cell lung cancer (NSCLC). However, manual evaluation of PD-L1 tumor proportion score (TPS) by pathologists has practical limitations of interobserver bias, variation in subjectivity on the area of interest, and intensive labor. Now, a new artificial intelligence (AI)-powered TPS analyzer could reduce the human discrepancy.

Lunit’s (Seoul, Korea) Lunit SCOPE PD-L1 TPS, an AI-based PD-L1 TPS analyzer, performs PD-L1 TPS classification which enhances objective and accurate analysis as compared to the traditional method. The product, trained with more than 1,000,000 cancer cell images, precisely analyzes PD-L1 biomarker expression and classifies PD-L1 TPS into three groups: 50% or more, 1-49%, and 0%. This digitized assistance substantially supports pathologists in diagnosing the status with high accuracy and consistency in analysis performance.

Lunit has received the CE-IVDD Mark for the Lunit SCOPE PD-L1 TPS. While Lunit's INSIGHT product scored the CE Mark in 2019 and 2020, this is the first time for a Lunit SCOPE product to receive European approval. The company is working on launching Lunit SCOPE PD-L1 in Europe within the second half of 2022, paving the way for deployment and use in European pathology practices.

"This CE Mark certification is a meaningful milestone," said Brandon Suh, CEO of Lunit. "It demonstrates the expansion of Lunit's offerings to the cancer biopsy field beyond the scope of medical image analysis. As our AI technology gains reliability and recognition, we will do our utmost to pioneer the overseas market."

Related Links:
Lunit 

New
Gold Supplier
Human Chorionic Gonadotropin (hCG) Test
OSOM hCG Combo Test
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test
New
Legionella Pneumophila Assay
C4Legio LFA
New
PLGF ELISA Kit
Placental Growth Factor ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.